I en multicenter, dobbeltblindet 12- ugers faktoriel undersøgelse reducerede Trevaclyn1. 000 mg/ 20 mg og simvastatin signifikant LDL- C (henholdsvis - 44, 2%, - 37, 4% og - 8, 2%), TG (henholdsvis - 25, 8%, - 15, 7% og - 18, 7%), TC (henholdsvis - 27, 9%, - 25, 8% og - 4, 9%), når det blev sammenlignet med simvastatin alene eller Trevaclyn 1. 000 mg/ 20 alene i 4 uger.
In a multicentre, double-blind, 12-week factorial study, Trevaclyn 1000 mg/ 20 mg co-administered with simvastatin, when compared with simvastatin alone or Trevaclyn 1000 mg/ 20 mg alone, for 4 weeks, significantly lowered LDL-C (-44.2%, -37.4%, -8.2% respectively), TG (-25.8%, -15.7%, -18.7% respectively), TC (-27.9%, -25.8%, -4.9% respectively) and significantly increased HDL-C (19.2%, 4.2%, 12.5% respectively).